At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Sample collection only (other)
- How long the study runs
- Study runs about 47 months (dates as stated)
- About the drug or intervention
- Sample collection only — other: Sample collection only
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 120
- Started
- 2023-03-23
- Last checked
- 2024-08
Plain English Summary
What is this study?
- • Testing a new treatment for thyroid cancer
- • Clinical study - 120 participants
- • Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with thyroid cancer
Where?
- • London - The Royal Marsden NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. This will eventually progress and at this point may become incurable with treatment options including complex and high risk surgery. The overall efficacy of systemic treatment in advanced thyroid cancer has a good initial response in most patients but not all. The study will collect tissues and blood samples for various protein analysis, nucleic acid extraction and live cell analysis in order to try and detect the presence of plasma ctDNA at baseline of eligible patients.
More detail
The treatment decisions are based on relying on radiological parameters such as using the RECIST criteria and measuring the rise in certain serum tumour biomarkers. However, the disadvantage of this is that this method can take many months to detect a change in disease volume. An improved understanding of genetics and cancer and potential gene sequencing can help achieve personalised treatment for patients. However, there are many questions and issues that still need to be answered and require urgent attention before being able to achieve optimate patient stratification. We need to identify better tumour biomarkers to detect disease progression, show real time response to treatment and understand why tumours evolve to becoming more aggressive. This study hopes to address these issues by proposing a multicentre prospective study to investigate the presence and role of ctDNA in advanced thyroid cancer including differentiated thyroid cancer , medullary thyroid cancer and Anaplastic Thyroid Cancer.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Age 18 years or older. (all cohorts)
- ✓Patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (RR-DTC) under surveillance. (cohort 1)
- ✓Patients with RR-DTC starting treatment that goes through your whole body Or Patients with RR-DTC on treatment that goes through your whole body Or Patients with MTC...
- ✓Patients with newly diagnosed anaplastic thyroid cancer (cohort 4)
- ✓Availability of tissue from one archival diagnostic tumour tissue block or be willing to have biopsy of accessible...
Who cannot take part
- ✗Previous or concurrent illness, which in the investigator's opinion would interfere with collection of the complete...
- ✗Any invasive cancer within previous 5 years (other than non-melanomatous skin carcinoma or carcinoma in situ)
- ✗Pregnancy
See the full criteria
Where Is This Study? (1 UK site)
The Royal Marsden NHS Foundation Trust
London SW3 6JJ, United Kingdom
How to Get in Touch
Leslie Cheng
Sponsor contactCONTACT